Clinical Trials

Adalimumab in psoriasis: The REVEAL (Randomized Controlled EValuation of Adalimumab Every Other Week Dosing in Moderate to Severe Psoriasis) study

Psoriasis patients with or without psoriatic arthritis experience improvements in skin and in patient-reported outcomes upon treatment with adalimumab: Results from the first 16 weeks of REVEAL

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here